Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from PFE

Pharma Stocks Analysis: Grab, Hold, or Sell?

Despite economic pressures and intensified competition, government incentives and drug innovations are fueling growth in the pharma sector. So, let us delve into the analysis of leading pharma stocks Bristol-Myers Squibb (BMY), Collegium Pharmaceutical (COLL), Pfizer (PFE), and Vaxcyte (PCVX), assessing whether to Grab, Hold, or Sell the stocks amid…

StockNews.com

Pfizer Stock 2025 Forecast: Will PFE Go Up Long Term?

Pfizer stock is trading at price levels last seen in 2016. The 2025 forecast for PFE stock looks positive, though, and it should go up over the medium to long term.

Barchart

Pharma Stock Analysis: Buy, Hold, or Sell These 4?

Amid rising global medical needs, an aging population, and technological advancements, the pharmaceutical industry is expected to witness robust growth over the coming years. Given this positive backdrop, let’s analyze the investment prospects of pharma stocks Madrigal (MDGL), Pfizer (PFE), Astellas (ALPMY), and Novo Nordisk (NVO). Read on.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer (PFE): Pre-Earnings Strategies

Pfizer (PFE) is facing hurdles due to weakened demand for its products and pipeline diversification challenges. Nevertheless, the company exhibits long-term potential through strategic acquisitions. Given this scenario, what course of action should be considered ahead of the upcoming earnings release? Read more to find out.

StockNews.com

Where Will Pfizer Stock Be in 1 Year?

PFE is a beaten-down healthcare stock that trades at a discount to consensus price target estimates. Is Pfizer stock a good buy right now?

Barchart

Pfizer (PFE) 2024 Preview: What to Expect From the Pharma Stock?

As Pfizer (PFE) navigates a post-pandemic world with a shifting focus away from COVID-related products, what should investors expect from this pharma giant? Let’s look at its financial metrics to know more….

StockNews.com

I’ve Got 5 Stocks and 5 DTEs: Which Call Should I Buy?

Wednesday’s unusual options activity had multiple stocks with two or more calls expiring on the same day. Five stocks caught my interest. Only one of the calls is worth buying.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Pfizer Inc. (PFE) vs. Taro Pharmaceutical (TARO) - Betting on Which Pharma Stock Will Have Q4 Dominance

The pharmaceutical industry’s prospects are driven by the rising occurrence of chronic diseases coupled with the adoption of cutting-edge technology. In this context, which company among the two major industry players, Pfizer Inc. (PFE) and Taro Pharmaceutical (TARO) are going to dominate the fourth quarter? Let’s find out….

StockNews.com

How to Buy PFE For a 7% Discount, or Achieve a 16% Annual Return

Selling cash secured puts on stocks an investor is happy to take ownership of is a great way to generate some extra income.

Barchart

Can Pfizer (PFE) and AbbVie (ABBV) Cure Your Portfolio's Ailments?

The pharmaceutical industry is expected to thrive amid robust demand and technological advancements. Amid this, let’s analyze the fundamentals of AbbVie (ABBV) and Pfizer (PFE) to determine whether these stocks are worth buying now.

StockNews.com

Is Pfizer (PFE) a Stock to Buy Following Its Q3 Earnings?

Pfizer (PFE) faces weakening demand for its COVID products, resulting in a topline decline in the third quarter. Should investors consider buying the stock now? Let’s look at its financial metrics to gauge its prospects….

StockNews.com

3 Pharma Stocks With Potential to Outperform Pfizer Inc. (PFE) in October

Pfizer (PFE) is grappling with financial difficulties and declining performance. Yet, with growing pharmaceutical demand and industry advancements, robust pharma stocks Zoetis (ZTS), Horizon Therapeutics (HZNP), and Novartis (NVS) appear as more promising buys this month. Read on.

StockNews.com

Which Pharma Stock Has More Potential Gains This Month: Pfizer (PFE) or Eli Lilly & Co. (LLY)?

The pharmaceutical industry is poised for sustained long-term growth due to increased investments in drug development and rapid technological advancements. While leading pharma stocks Pfizer (PFE) and Eli Lilly (LLY) stand to benefit, let us analyze which of these giants is poised for more gains this month. Keep reading.

StockNews.com

3 Recession-Proof Stocks to Buy Now

Some recent economic data points have revived recession fears, sending equities sharply lower this September. Here are 3 recession-proof stocks that conservative investors can consider now.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Pfizer Inc. (PFE) – Buy or Hold Analysis on This Pharma Stock

Leading pharma company Pfizer (PFE) is struggling to recover from waning Covid vaccine demand and is eyeing cost-cutting measures. So, is the stock worth buying? Read on.

StockNews.com

3 Pharma Stocks to Watch for Value in September

The pharmaceutical industry enjoys robust demand irrespective of economic cycles. Also, given its solid growth prospects, I think pharma stocks Pfizer (PFE), Catalyst Pharmaceuticals (CPRX), and Kiniksa Pharmaceuticals (KNSA) might be worth adding to one’s watchlist for value. Read on.

StockNews.com

Pfizer Inc. (PFE) vs. Teva Pharmaceutical Industries (TEVA): Which Stock is the Better Growth AND Value Buy?

The pharmaceutical sector appears to be in a favorable position for sustained long-term expansion. While leading pharma stocks Pfizer (PFE) and Teva Pharmaceuticals (TEVA) should benefit from the industry tailwinds, let us analyze which is the better buy for Growth and Value.

StockNews.com

Looking for a Value Investment? Check out These 3 Pharma Stocks

The pharmaceutical industry looks well-positioned for long-term growth. Therefore, fundamentally strong Merck & Co (MRK), Pfizer (PFE), and Lipocine (LPCN) could be ideal value investments now. Keep reading.

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Should Value Investors Go After Pfizer (PFE)?

Pfizer Inc (PFE), currently trading at a discount, is charting a path to enduring expansion via strategic acquisitions and the introduction of novel products. Despite this drive, recent financial results lack significant optimism. Given this scenario, should investors invest in PFE? Let’s look at its financial metrics to gauge its…

StockNews.com

3 Pharma Stocks Investors Are Chasing for Value

With the advent of advanced medications and the increasing need for personalized treatments, the pharmaceutical industry looks well-poised for long-term growth. Therefore, it could be worth looking into three fundamentally sound pharma stocks, Pfizer (PFE), Sanofi (SNY), and GSK plc (GSK), that are offering significant value. Read more….

StockNews.com

Are Pfizer (PFE) and AbbVie (ABBV) Good Value Buys for August?

The pharma industry is poised to witness long-term growth with the introduction of generic medicines and growing demand for personalized and targeted treatments. Hence, fundamentally strong pharma stock AbbVie (ABBV) might be worth buying. However, it might not be the right time to invest in Pfizer (PFE). Keep reading.

Barchart

Is the Rally Getting Long in the Tooth? Try These Bear Call Spread Trades

Traders should have a bearish outlook on the stock and ideally look to enter when the stock has a high implied volatility rank.

StockNews.com

Is AbbVie (ABBV) a Better Stock to Buy Than Pfizer (PFE)?

Due to the emergence of new technologies and the introduction of generic medicines, the pharma industry seems well-positioned to witness growth. While pharma stocks should benefit from the industry tailwinds, let us analyze whether AbbVie (ABBV) is a better buy than Pfizer (PFE).

Barchart

Should You Buy the Dip in Pfizer Stock? Here's What You Need to Know

US stock markets delivered stellar returns in the first half of the year and the Nasdaq 100 had its best first-half performance ever. However, Pfizer, whose COVID-19 vaccine made the company a household name recently fell to a 52-week low. Why is Pfizer stock going down and should you buy…

StockNews.com

Should Value Investors Watch Pfizer (PFE)?

Pfizer (PFE) is spending its COVID-19 cash flows on meaningful growth avenues. However, given a recent downgrade, should value investors still be excited about this stock? Let’s look at the trends of its financial metrics to get an idea….

1 … 5 6 7 8

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

722 stories

Steve Reitmeister

508 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.